Landers Zakary D, Mazhar Asra
Osteopathic Medicine, Pacific Northwest University of Health Sciences, Yakima, USA.
Family Medicine, Overlake Medical Center, Bellevue, USA.
Cureus. 2024 May 27;16(5):e61174. doi: 10.7759/cureus.61174. eCollection 2024 May.
Fluoroquinolones are widely prescribed antibiotics with well-known, mostly transient adverse effects, the most common of which are gastrointestinal disturbances, headaches, dizziness, rash, etc. However, a less recognized yet profoundly debilitating complication exists known as fluoroquinolone-associated disability (FQAD), operationally defined as impacting at least two systems (neurological, musculoskeletal, psychiatric, and/or cardiovascular) for at least 30 days post-cessation of a fluoroquinolone and with an outcome reported as disability. Unfortunately, this syndrome has yet to be formally recognized by the medical community. As such, FQAD patients are rarely diagnosed and undergo extensive diagnostic testing, leading to unnecessary costs to the patient and our healthcare system. Herein, we present the case of a 41-year-old male patient who developed acute bilateral numbness and tingling in his upper and lower extremities after just two doses of ciprofloxacin for epididymitis. Despite extensive evaluations from various specialists and therapists over the following 18 months, his symptoms continued to progress without any clear insight into the cause of his symptoms. He eventually reached out to an FQAD specialist due to his own suspicions and began therapy with hyperbaric oxygen, IV magnesium, and IV glutathione. Mild improvement was noted from these therapies, but he was unable to undergo regular treatments due to the financial debt acquired from his extensive medical workups and ultimately stopped treatment completely without any further improvements. Our case report highlights the importance of early recognition of FQAD to start prompt treatment and avoid costly testing. Overall, we aim to raise awareness of FQAD among clinicians as a potential complication of fluoroquinolone use.
氟喹诺酮类药物是广泛使用的抗生素,其不良反应大多为人熟知且多为短暂性,最常见的有胃肠道不适、头痛、头晕、皮疹等。然而,存在一种较少被认识但严重致残的并发症,称为氟喹诺酮类药物相关残疾(FQAD),其操作定义为在停用氟喹诺酮类药物后至少30天内影响至少两个系统(神经、肌肉骨骼、精神和/或心血管系统),且报告结果为残疾。不幸的是,这种综合征尚未得到医学界的正式认可。因此,FQAD患者很少被诊断出来,并且要接受广泛的诊断测试,给患者和我们的医疗系统带来不必要的费用。在此,我们报告一例41岁男性患者的病例,该患者因附睾炎仅服用两剂环丙沙星后就出现了双侧上下肢急性麻木和刺痛。在接下来的18个月里,尽管接受了各种专科医生和治疗师的广泛评估,他的症状仍持续进展,对其症状的原因没有任何明确的认识。由于他自己的怀疑,他最终联系了一位FQAD专家,并开始接受高压氧、静脉注射镁和静脉注射谷胱甘肽治疗。这些治疗有轻微改善,但由于他因广泛的医学检查而背负的经济债务,他无法接受常规治疗,最终完全停止治疗,没有任何进一步改善。我们的病例报告强调了早期识别FQAD以开始及时治疗并避免昂贵检查的重要性。总体而言,我们旨在提高临床医生对FQAD作为氟喹诺酮类药物使用潜在并发症的认识。